1. Home
  2. EQR vs RMD Comparison

EQR vs RMD Comparison

Compare EQR & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Equity Residential of Beneficial Interest

EQR

Equity Residential of Beneficial Interest

HOLD

Current Price

$66.87

Market Cap

24.3B

Sector

Real Estate

ML Signal

HOLD

Logo ResMed Inc.

RMD

ResMed Inc.

HOLD

Current Price

$200.54

Market Cap

28.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EQR
RMD
Founded
1993
1989
Country
United States
United States
Employees
N/A
10600
Industry
Real Estate Investment Trusts
Medical/Dental Instruments
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.3B
28.4B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
EQR
RMD
Price
$66.87
$200.54
Analyst Decision
Buy
Buy
Analyst Count
13
10
Target Price
$69.63
$292.56
AVG Volume (30 Days)
2.9M
1.5M
Earning Date
04-28-2026
04-30-2026
Dividend Yield
4.29%
1.13%
EPS Growth
8.09
N/A
EPS
0.24
N/A
Revenue
$2,701,075,000.00
N/A
Revenue This Year
$4.07
$10.60
Revenue Next Year
$3.14
$7.41
P/E Ratio
$275.63
$25.61
Revenue Growth
4.76
N/A
52 Week Low
$57.57
$180.27
52 Week High
$69.03
$293.81

Technical Indicators

Market Signals
Indicator
EQR
RMD
Relative Strength Index (RSI) 55.48 54.34
Support Level $58.62 $198.63
Resistance Level $69.03 $260.21
Average True Range (ATR) 1.32 4.40
MACD -0.15 1.45
Stochastic Oscillator 60.63 88.41

Price Performance

Historical Comparison
EQR
RMD

About EQR Equity Residential of Beneficial Interest

Equity Residential owns a portfolio of 318 apartment communities with over 86,000 units and is developing three additional properties with 935 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.

About RMD ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.

Share on Social Networks: